慢性心力衰竭患者内源性促红细胞生成素的改变及临床意义  

Change of Endogenous Erythropoietin in Patients with ChronicHeart Failure and Its Clinical Significance

作　　者：郭玲[1] 许崇恩[2] 孙永乐[1] 吕琳[1] 王爱红[1] 

机构地区：[1]山东大学附属省立医院心内科,山东济南200021 [2]山东大学附属省立医院心外科,山东济南200021

出　　处：《现代生物医学进展》2011年第19期3716-3718,3741,共4页Progress in Modern Biomedicine

基　　金：山东省自然基金项目(Y2007C052)

摘　　要：目的:探讨内源性促红细胞生成素(EPO)在慢性心力衰竭(CHF)及CHF贫血发病中的作用及临床价值。方法:采用放射性免疫分析法测定117例CHF患者和40例非CHF患者血浆EPO水平,分析EPO水平与心功能分级、贫血以及CHF患者预后的关系。结果:心功能II～IV患者EPO水平显著上升,与对照组比较均有显著性差异(P<0.05);EPO水平随着心功能分级增高而逐渐上升,在各级间比较有显著性差异(P<0.05);CHF伴贫血患者EPO水平随着心功能分级增高和贫血程度的加重而逐渐上升,在各级间比较有显著性差异(P<0.05);死亡组EPO水平显著高于存活组,而Hb水平显著低于存活组,相比较有显著性差异(P<0.05)。结论:CHF患者和CHF伴贫血患者内源性EPO水平升高,EPO水平的上升与CHF患者病情严重程度有关,并且是CHF患者预后不良的预测指标。Objective： To investigate the change of endogenous erythropoietin （EPO） in patients with chronic heart failure （CHF） and its clinical significance. Methods： The plasma EPO level of 117 cases of patients with CHF and 40 cases of patients with non- CHF was measured by radioimmunoassay method. The correlation of EPO level and cardiac function, anemia and prognosis of CHF was analyzed. Results： The EPO level of patients with cardiac fimction II - IV significantly increased, compared with the control group the different was significant （P 〈0.05）; The EPO level of CHF patients increased with the cardiac function gradually increased, the differences was significant in cardiac function II - IV （P 〈0.05）; The EPO level of patients with CHF combined anemia increased with the cardiac function gradually increased and the aggravation of serious degree of anemia, the differences was significant （P 〈0.05）; The EPO level of death group was higher than the survival group and the Hb level of death group was lower than the survival group, the difference was significant between the two groups （P 〈0.05）. Conclusion： The endogenous EPO level of patients with CHF and CHF combined anemia increase, the EPO level relates to the severity of CHF, and is a predictor of poor prognosis.

关 键 词：慢性心力衰竭 促红细胞生成素 内源性 贫血 心功能 预后 

分 类 号：R541.61[医药卫生—心血管疾病]